Published in Gut on October 01, 2007
Current prophylactic strategies against hepatitis B virus recurrence after liver transplantation. World J Gastroenterol (2009) 0.78
Study on Post-Treatment Relapse in HBeAg Positive CHB Patients. PLoS One (2015) 0.75
Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med (2005) 7.18
Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet (2005) 3.33
Long-term remission of chronic hepatitis B after alpha-interferon therapy. Ann Intern Med (1991) 1.92
Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. Hepatology (2004) 1.59
Long-term results of lamivudine monotherapy in Korean patients with HBeAg-positive chronic hepatitis B: response and relapse rates, and factors related to durability of HBeAg seroconversion. Intervirology (2005) 0.98
Predicting relapse after cessation of Lamivudine monotherapy for chronic hepatitis B virus infection. Clin Infect Dis (2004) 0.89
Antiviral effect of prolonged intermittent lymphoblastoid alpha interferon treatment in chronic hepatitis B. Gut (1992) 0.85
Which patients with chronic hepatitis B are more likely to relapse after interferon alpha-induced hepatitis B e antigen loss in Korea? J Clin Gastroenterol (2004) 0.84
Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology (1997) 5.53
Acute liver failure: redefining the syndromes. Lancet (1993) 4.99
European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut (2006) 3.59
Lamivudine resistance in immunocompetent chronic hepatitis B. Incidence and patterns. J Hepatol (1997) 2.86
Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology (1992) 2.82
Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology (2001) 2.81
Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut (2000) 2.55
Subclinical hepatic encephalopathy impairs daily functioning. Hepatology (1998) 2.23
The clinicopathological and prognostic relevance of cytokeratin 7 and 19 expression in hepatocellular carcinoma. A possible progenitor cell origin. Histopathology (2006) 2.18
Colonic explosion during endoscopic polypectomy: avoidable complication or bad luck? Endoscopy (2006) 2.10
The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference*. J Viral Hepat (2011) 2.00
Major coagulation disturbances during fractionated plasma separation and adsorption. Am J Transplant (2007) 1.97
Screening of subclinical hepatic encephalopathy. J Hepatol (2000) 1.96
Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial. Am J Transplant (2012) 1.88
Extrahepatic portal vein thrombosis: aetiology and determinants of survival. Gut (2001) 1.86
Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis. European Concerted Action on Viral Hepatitis (EUROHEP) Am J Gastroenterol (1998) 1.74
Early cirrhosis--or primary cholangitis? Lancet (1997) 1.74
Glycyrrhizin-induced reduction of ALT in European patients with chronic hepatitis C. Am J Gastroenterol (2001) 1.72
Vascular liver disorders (I): diagnosis, treatment and prognosis of Budd-Chiari syndrome. Neth J Med (2008) 1.67
Hepatitis C virus in lymphoid cells of patients coinfected with human immunodeficiency virus type 1: evidence of active replication in monocytes/macrophages and lymphocytes. J Infect Dis (2000) 1.66
Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy. Gut (2004) 1.65
Association of coeliac disease and inflammatory bowel disease. Gut (1980) 1.62
Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. The EUROHEP Study Group on Hepatitis B Virus and Cirrhosis. Hepatology (1995) 1.57
Review article: chronic hepatitis B - anti-viral or immunomodulatory therapy? Aliment Pharmacol Ther (2010) 1.56
Hepatitis B vaccination and preterm infants. Pediatr Infect Dis J (1993) 1.55
Renal function at two years in liver transplant patients receiving everolimus: results of a randomized, multicenter study. Am J Transplant (2013) 1.54
Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection. J Viral Hepat (2003) 1.53
Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections in health care workers (HCWs): guidelines for prevention of transmission of HBV and HCV from HCW to patients. J Clin Virol (2003) 1.53
The impact of FCN2 polymorphisms and haplotypes on the Ficolin-2 serum levels. Scand J Immunol (2007) 1.51
Safety of interferon and ribavirin therapy in haemodialysis patients with chronic hepatitis C: results of a pilot study. Nephrol Dial Transplant (2001) 1.50
Idiopathic noncirrhotic portal hypertension is associated with poor survival: results of a long-term cohort study. Aliment Pharmacol Ther (2012) 1.49
Budesonide or prednisone in combination with ursodeoxycholic acid in primary sclerosing cholangitis: a randomized double-blind pilot study. Belgian-Dutch PSC Study Group. Am J Gastroenterol (2000) 1.49
Ambulatory 24 hour intraoesophageal pH and pressure recordings v provocation tests in the diagnosis of chest pain of oesophageal origin. Gut (1990) 1.48
Does auxiliary heterotopic liver transplantation reverse hypersplenism and portal hypertension? Gastroenterology (1991) 1.44
Ten-year neonatal hepatitis B vaccination program, The Netherlands, 1982-1992: protective efficacy and long-term immunogenicity. Vaccine (1997) 1.44
The prognostic significance of subclinical hepatic encephalopathy. Am J Gastroenterol (2000) 1.44
Soluble intercellular adhesion molecule-1 in primary biliary cirrhosis: effect of ursodeoxycholic acid and immunosuppressive therapy. Eur J Gastroenterol Hepatol (1997) 1.42
Identification of more than one mutation in the hepatitis B virus polymerase gene arising during prolonged lamivudine treatment. J Infect Dis (1998) 1.42
Molecular cytogenetic evaluation of virus-associated and non-viral hepatocellular carcinoma: analysis of 26 carcinomas and 12 concurrent dysplasias. J Pathol (2000) 1.41
'Pseudo-aldosteronism' induced by intravenous glycyrrhizin treatment of chronic hepatitis C patients. J Gastroenterol Hepatol (2001) 1.41
Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study. The Investigators of the European Concerted Action on Viral Hepatitis (EUROHEP). J Hepatol (1994) 1.40
[Diagnosis of 5 patients with possible primary hemochromatosis]. Ned Tijdschr Geneeskd (2003) 1.39
[Clinical thinking and decision-making in practice. A pregnant Turkish woman with a liver tumor]. Ned Tijdschr Geneeskd (2000) 1.39
Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy. Hepatology (2000) 1.38
Definition of MHC and T cell receptor contacts in the HLA-DR4restricted immunodominant epitope in type II collagen and characterization of collagen-induced arthritis in HLA-DR4 and human CD4 transgenic mice. Proc Natl Acad Sci U S A (1998) 1.38
European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. European Concerted Action on Viral Hepatitis (EUROHEP) Group. Gastroenterology (1999) 1.38
A randomized trial in primary biliary cirrhosis comparing ursodeoxycholic acid in daily doses of either 10 mg/kg or 20 mg/kg. Dutch Multicentre PBC Study Group. Aliment Pharmacol Ther (1998) 1.38
Inosine prabonex in the treatment of chronic hepatitis C. J Hepatol (1992) 1.38
Plasma collected from heparinized blood is not suitable for HCV-RNA detection by conventional RT-PCR assay. J Virol Methods (1993) 1.38
Inhibitory effect of 9-(2-phosphonylmethoxyethyl)-adenine (PMEA) on human and duck hepatitis B virus infection. Antiviral Res (1993) 1.37
Inhibitory effects of acyclic nucleoside phosphonates on human hepatitis B virus and duck hepatitis B virus infections in tissue culture. Antimicrob Agents Chemother (1994) 1.36
Predictors for neoplastic progression in patients with Barrett's Esophagus: a prospective cohort study. Am J Gastroenterol (2011) 1.36
Review article: glycyrrhizin as a potential treatment for chronic hepatitis C. Aliment Pharmacol Ther (1998) 1.36
Contrasting features and responses to treatment of severe chronic active liver disease with and without hepatitis BS antigen. Gut (1976) 1.35
Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection. Hepatology (2001) 1.32
Suicide associated with alfa-interferon therapy for chronic viral hepatitis. J Hepatol (1994) 1.31
Exacerbation of chronic hepatitis B infection after delivery. J Viral Hepat (2008) 1.31
Sequence analysis of the 5' untranslated region in isolates of at least four genotypes of hepatitis C virus in The Netherlands. J Clin Microbiol (1994) 1.30
The renal histopathology in systemic vasculitis: an international survey study of inter- and intra-observer agreement. Nephrol Dial Transplant (1996) 1.25
Passive-active immunisation of neonates of HBsAg positive carrier mothers: preliminary observations. Br Med J (Clin Res Ed) (1984) 1.25
A recombinant antibody with the antigen-specific, major histocompatibility complex-restricted specificity of T cells. Proc Natl Acad Sci U S A (1996) 1.24
Intravenous glycyrrhizin for the treatment of chronic hepatitis C: a double-blind, randomized, placebo-controlled phase I/II trial. J Gastroenterol Hepatol (1999) 1.21
Interferon alfa for chronic hepatitis B infection: increased efficacy of prolonged treatment. The European Concerted Action on Viral Hepatitis (EUROHEP). Hepatology (1999) 1.21
Behaviour of e antigen and antibody during chronic active liver disease. Relation to HB antigen-antibody system and prognosis. Lancet (1976) 1.20
Efficacy of interferon dose and prediction of response in chronic hepatitis C: Benelux study in 336 patients. J Hepatol (1998) 1.20
Predictive value of liver cell dysplasia for development of hepatocellular carcinoma in patients with non-cirrhotic and cirrhotic chronic viral hepatitis. Histopathology (2001) 1.20
Systematic review: the pathophysiology and management of polycystic liver disease. Aliment Pharmacol Ther (2011) 1.19
Systematic review and meta-analysis of the association between diabetes mellitus and incidence and mortality in breast and colorectal cancer. Br J Surg (2013) 1.19
Mechanical factors influencing the incidence of burst abdomen. Eur J Surg (1995) 1.18
The independent prognostic value of comorbidity among men aged < 75 years with localized prostate cancer: a population-based study. BJU Int (2001) 1.18
Determinants of quality of life in chronic liver patients. Aliment Pharmacol Ther (2006) 1.18
The long-term outcome of patients with polycystic liver disease treated with lanreotide. Aliment Pharmacol Ther (2011) 1.17
Hepatitis C virus negative strand RNA is not detected in peripheral blood mononuclear cells and viral sequences are identical to those in serum: a case against extrahepatic replication. J Gen Virol (1997) 1.17
Detection of active hepatitis C virus and hepatitis G virus/GB virus C replication in bone marrow in human subjects. Blood (2000) 1.16
Proposal for routine antenatal screening at 14 weeks for hepatitis B surface antigen. Dutch Study Group on Prevention of Neonatal Hepatitis. BMJ (1995) 1.16
Hepatitis B reactivation after lamivudine. Lancet (1995) 1.15
Auxiliary partial liver transplantation for end-stage chronic liver disease. N Engl J Med (1988) 1.14
Quantitative assessment of hepatitis B virus DNA in chronic hepatitis B: comparison of two solution hybridization assays. J Med Virol (1993) 1.13
Acyclovir enhances the antiviral effect of interferon in chronic hepatitis B. Lancet (1985) 1.12
Effect of liquid diet on serum protein binding and prednisolone concentrations after oral prednisone. Gastroenterology (1976) 1.10
Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. European Concerted Action on Viral Hepatitis (EUROHEP). J Hepatol (1997) 1.09